# iShares U.S. Pharmaceuticals ETF

Type: Product (IHE)

Source: Finance Intelligence Brief — https://getfinancebrief.com/entity/ishares-us-pharmaceuticals-etf
Canonical HTML page: https://getfinancebrief.com/entity/ishares-us-pharmaceuticals-etf

## Recent coverage (2 stories)

### IHE vs IXJ: 0.39% vs 0.41% Fees — Which Healthcare ETF Wins?
2026-07-19 06:02:54 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

The iShares U.S. Pharmaceuticals ETF (IHE) and iShares Global Healthcare ETF (IXJ) differ in expense ratios (0.39% vs 0.41%), AUM ($1.4B vs $4.1B), and diversification (56 vs 110 holdings). For finance professionals, the 0.02% fee gap may tip the scales for cost-conscious portfolios, but liquidity and global exposure often justify IXJ's slightly higher expense.
Full story: https://getfinancebrief.com/story/ihe-ixj-healthcare-etf-fee-comparison

### BlackRock’s iShares Healthcare ETFs Signal Stability with Quarterly Payouts
2026-03-17 08:20:40 · Sentiment: Neutral · Impact: 5/10 · Sources: 3

BlackRock has announced quarterly distributions for three major healthcare-focused iShares ETFs, reflecting the varied cash flow profiles across the pharmaceutical, medical device, and healthcare provider sub-sectors. The distributions, led by the $0.2845 per share payout for the U.S. Pharmaceuticals ETF (IHE), come as investors weigh sector-specific regulatory pressures against robust balance sheets.
Full story: https://getfinancebrief.com/story/ishares-healthcare-etf-quarterly-distributions-2026

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getfinancebrief.com/guides/methodology for the full editorial methodology.